Darolutamide: Advancing Care for Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

Dr Daniel George highlights the efficacy and safety of darolutamide in treating non-metastatic castration-resistant prostate cancer (nmCRPC). Drawing on compelling data from Phase III trials and real-world studies, he emphasizes darolutamide's ability to significantly delay disease progression and improve overall survival with minimal adverse effects compared to enzalutamide and apalutamide. Unlike older agents, darolutamide’s unique molecular structure limits blood-brain barrier penetration, reducing side effects like fatigue, cognitive impairment, and falls. Real-world data further confirm its tolerability and lower discontinuation rates. This evidence underscores darolutamide as a highly effective and patient-friendly treatment option, improving outcomes while preserving quality of life.